Beta-Blocker Use and Lung Cancer Mortality in a Nationwide Cohort Study of Patients with Primary Non-Small Cell Lung Cancer.

Ruzan UdumyanScott MontgomeryFang FangUnnur ValdimarsdottirHronn HardardottirAnders EkbomKarin E SmedbyKatja Fall

Published in: Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology (2019)

Our results do not indicate that β-blocker use at lung cancer diagnosis reduces the cancer-specific mortality rate in patients with NSCLC.

Keyphrases

cardiovascular events
small cell lung cancer
papillary thyroid
risk factors
angiotensin converting enzyme
squamous cell
cardiovascular disease
squamous cell carcinoma
coronary artery disease
lymph node metastasis